Aurore Daron

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 237 citations

Gene Therapies, Clinical Trials, Neurology +2

Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study

A. Chabanon, A. Seferian, Aurore Daron et al. · PLoS ONE · 2018 · 146 citations · Full text

Nusinersen in patients older than 7 months with spinal muscular atrophy type 1

Karolina Aragon‐Gawinska, Andreea Seferian, Aurore Daron et al. · Neurology · 2018 · 117 citations

Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study

M. Annoussamy, A. Seferian, Aurore Daron et al. · Annals of Clinical and Translational Neurology · 2020 · 109 citations · Full text

X-linked myotubular myopathy

M. Annoussamy, C. Lilien, Teresa Gidaro et al. · Neurology · 2019 · 88 citations · Full text